title: [Results of chemo-radiotherapy for nasopharyngeal carcinoma].
abstract: We reported the data on 25 patients with nasopharyngeal carcinoma from 1984 to 1989, who received chemo-radiotherapy for initial treatment and follow-up by additional maintenance of chemotherapy for 2 years. The result of this study is as follows. 1. The 20 males and 5 females were included. 2. A median age of the patients was 62 years. 3. Stage grouping study showed 3 cases of stage II, 6 of stage III, and 16 of stage IV. 4. The local control rate was 92% and the rate of control in the cervical region was 96%. 5. However, the overall 4-year survival rate obtained by the Kaplan-Meiers method was 50%. 6. The cause of patients' death was mainly distant metastasis.
authors.affiliation: Mizojiri Clinic Otorhinolaryngology, Nishinomiya.
authors.forename: G
authors.initials: G
authors.lastname: Mizojiri
authors.forename: Y
authors.initials: Y
authors.lastname: Shiba
authors.forename: K
authors.initials: K
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Hoshino
authors.forename: T
authors.initials: T
authors.lastname: Nozaki
authors.forename: K
authors.initials: K
authors.lastname: Yamada
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D017663:Peplomycin; D011879:Radiotherapy Dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D017663:Peplomycin; D014750:Vincristine; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil